GM-CSF Antibody (A-6): sc-377039
- GM-CSF Antibody (A-6) is a mouse monoclonal IgG1 κ, cited in 2 publications, provided at 200 µg/ml
- specific for an epitope mapping between amino acids 115-144 at the C-terminus of GM-CSF of human origin
- recommended for detection of GM-CSF of human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP is the preferred secondary detection reagent for GM-CSF Antibody (A-6) for WB applications. This reagent is now offered in a bundle with GM-CSF Antibody (A-6) (see ordering information below).
QUICK LINKS
SEE ALSO...
GM-CSF Antibody (A-6) is a mouse monoclonal IgG1 antibody that detects GM-CSF in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-GM-CSF antibody (A-6) recognizes human granulocyte-macrophage colony-stimulating factor, a crucial pleiotropic cytokine that plays a significant role in the immune response by stimulating the proliferation and differentiation of hematopoietic progenitor cells into granulocytes and macrophages. GM-CSF (A-6) antibody targets a protein primarily secreted by activated T cells, macrophages, and endothelial cells, with enhanced survival and function of these immune cells being vital for effective host defense against infections and in the regulation of inflammatory responses. GM-CSF monoclonal antibody (A-6) recognizes a glycoprotein that undergoes post-translational modifications, including glycosylation, which can influence stability, activity, and interactions with specific receptors on target cells. Understanding these modifications is essential, as they can affect the therapeutic potential of GM-CSF in clinical applications, such as in the treatment of certain cancers and autoimmune diseases.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
GM-CSF Antibody (A-6) References:
- GM-CSF as a therapeutic target in inflammatory diseases. | van Nieuwenhuijze, A., et al. 2013. Mol Immunol. 56: 675-82. PMID: 23933508
- Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines. | Yu, TW., et al. 2016. Hum Vaccin Immunother. 12: 3020-3028. PMID: 27560197
- GM-CSF Promotes Antitumor Immunity by Inducing Th9 Cell Responses. | Kim, IK., et al. 2019. Cancer Immunol Res. 7: 498-509. PMID: 30728152
- G-CSF and GM-CSF Modify Neutrophil Functions at Concentrations found in Cystic Fibrosis. | Castellani, S., et al. 2019. Sci Rep. 9: 12937. PMID: 31506515
- Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. | Papiris, SA., et al. 2020. N Engl J Med. 382: 197. PMID: 31914249
- GM-CSF Primes Proinflammatory Monocyte Responses in Ankylosing Spondylitis. | Shi, H., et al. 2020. Front Immunol. 11: 1520. PMID: 32765525
- Construction of Recombinant Human GM-CSF and GM-CSF-ApoA-I Fusion Protein and Evaluation of Their Biological Activity. | Pykhtina, M., et al. 2021. Pharmaceuticals (Basel). 14: PMID: 34068113
- GM-CSF suppresses antioxidant signaling and drives IL-1β secretion through NRF2 downregulation. | Di Carlo, S., et al. 2022. EMBO Rep. 23: e54226. PMID: 35695080
- GM-CSF Promotes the Development of Dysfunctional Vascular Networks in Moyamoya Disease. | Li, H., et al. 2024. Neurosci Bull. 40: 451-465. PMID: 38113014
- TL1A and IL-18 synergy promotes GM-CSF-dependent thymic granulopoiesis in mice. | Ruiz Pérez, M., et al. 2024. Cell Mol Immunol. 21: 807-825. PMID: 38839915
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GM-CSF Antibody (A-6) | sc-377039 | 200 µg/ml | $322.00 | |||
GM-CSF Antibody (A-6): m-IgG Fc BP-HRP Bundle | sc-540686 | 200 µg Ab; 10 µg BP | $361.00 | |||
GM-CSF (A-6) Neutralizing Peptide | sc-377039 P | 100 µg/0.5 ml | $69.00 |